{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:28:05Z","timestamp":1787318885054,"version":"build-2736575974"},"reference-count":222,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["EMDR\/SG\/15\/2023-5901"],"award-info":[{"award-number":["EMDR\/SG\/15\/2023-5901"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRP-2023\\u20135901"],"award-info":[{"award-number":["IIRP-2023\\u20135901"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.prp.2025.156113","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T14:06:46Z","timestamp":1752588406000},"page":"156113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Interferon alpha-2b (IFN\u03b12b) in precision oncology: Innovations in delivery and combinatorial immunotherapy"],"prefix":"10.1016","volume":"273","author":[{"given":"Soham","family":"Bindu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archishman","family":"Ash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koustav","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2025.156113_bib1","first-page":"530","article-title":"Antineoplastic Drugs","author":"Kwok","year":"2017","journal-title":"Pharmacol. Ther. Dent. Seven.. Ed."},{"key":"10.1016\/j.prp.2025.156113_bib2","unstructured":"RCSB PDB - 1RH2: RECOMBINANT HUMAN INTERFERON-ALPHA 2B, (n.d.). \u3008https:\/\/www.rcsb.org\/structure\/1RH2\u3009 (accessed May 1, 2025)."},{"key":"10.1016\/j.prp.2025.156113_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.gene.2015.04.087","article-title":"IFNA2: The prototypic human alpha interferon","volume":"567","author":"Paul","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.prp.2025.156113_bib4","article-title":"Effect of promoter strength and signal sequence on the periplasmic expression of human interferon-\u03b12b in Escherichia coli","author":"Abiodun","year":"2010","journal-title":"Afr. J. Biotechnol."},{"key":"10.1016\/j.prp.2025.156113_bib5","unstructured":"Human IFN-Alpha 2b Protein (11105-1) | PBL Assay Science, (n.d.). \u3008https:\/\/www.pblassaysci.com\/proteins\/human-ifn-alpha-2-alpha-2b-11105\u3009 (accessed May 3, 2025)."},{"key":"10.1016\/j.prp.2025.156113_bib6","first-page":"253","article-title":"The past, present and future of immunotherapy against tumor","volume":"4","author":"Jiang","year":"2015","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.prp.2025.156113_bib7","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3390\/pharmaceutics15020504","article-title":"Recent Advances in Cancer Immunotherapy Delivery Modalities","volume":"15","author":"Muthukutty","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.prp.2025.156113_bib8","first-page":"1","article-title":"Exosome-based immunotherapy as an innovative therapeutic approach in melanoma","volume":"22","author":"Babaei","year":"2024","journal-title":"Cell Commun. Signal. 2024"},{"key":"10.1016\/j.prp.2025.156113_bib9","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1745-7254.2005.00188.x","article-title":"Multivesicular liposome formulations for the sustained delivery of interferon \u03b1-2b","volume":"26","author":"Qiu","year":"2005","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.prp.2025.156113_bib10","unstructured":"Interferon alfa-2b: Uses, Interactions, Mechanism of Action | DrugBank Online, (n.d.). https:\/\/go.drugbank.com\/drugs\/DB00105 (accessed February 27, 2025)."},{"key":"10.1016\/j.prp.2025.156113_bib11","unstructured":"Interferon alfa-2b (injection route) - Mayo Clinic, (n.d.). \u3008https:\/\/www.mayoclinic.org\/drugs-supplements\/interferon-alfa-2b-injection-route\/description\/drg-20071328\u3009 (accessed May 10, 2025)."},{"key":"10.1016\/j.prp.2025.156113_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-022-00415-y","article-title":"Direct and indirect effects of IFN-\u03b12b in malignancy treatment: not only an archer but also an arrow","volume":"10","author":"Xiong","year":"2022","journal-title":"Biomark. Res"},{"key":"10.1016\/j.prp.2025.156113_bib13","first-page":"1","article-title":"Human Interferon Alpha-2b: A Therapeutic Protein for Cancer Treatment","volume":"2014","author":"Asmana Ningrum","year":"2014","journal-title":"Sci. (Cairo)"},{"key":"10.1016\/j.prp.2025.156113_bib14","unstructured":"Interferon Alpha 2B: View Uses, Side Effects and Medicines | 1mg, (n.d.). \u3008https:\/\/www.1mg.com\/generics\/interferon-alpha-2b-210042?srsltid=AfmBOorKeRxNuqjcWjgpfZY984Upv3LAM-AuX46gmyto8bWfh7eTQisV\u3009 (accessed June 27, 2025)."},{"issue":"11","key":"10.1016\/j.prp.2025.156113_bib15","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41423-020-00549-9","article-title":"The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt\/\u03b2-catenin signaling pathway","volume":"17","author":"Deng","year":"2020","journal-title":"Cell. Mol. Immunol. 2020"},{"key":"10.1016\/j.prp.2025.156113_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2021.10.034","article-title":"Wnt signaling pathway in cancer immunotherapy","volume":"525","author":"Zhou","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2025.156113_bib17","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.ejca.2005.03.022","article-title":"Involvement of both intrinsic and extrinsic pathways in IFN-\u03b3-induced apoptosis that are enhanced with cisplatin","volume":"41","author":"Barton","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2025.156113_bib18","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.3390\/ijms17111832","article-title":"Interferon \u03b1 Induces the Apoptosis of Cervical Cancer HeLa Cells by Activating both the Intrinsic Mitochondrial Pathway and Endoplasmic Reticulum Stress-Induced Pathway","volume":"17","author":"Shi","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156113_bib19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1665-2681(19)31982-9","article-title":"Interferon alfa-2b triggers transforming growth factor-\u03b21-induced apoptosis on preneoplastic liver","volume":"5","author":"Cristina Carrillo","year":"2006","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.prp.2025.156113_bib20","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1038\/sj.onc.1206503","article-title":"Interferon-\u03b1-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax","volume":"22","author":"Panaretakis","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2025.156113_bib21","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1053\/jhep.2002.32099","article-title":"The in vivo apoptotic effect of interferon alfa-2b on rat preneoplastic liver involves bax protein","volume":"35","author":"de Luj\u00e1n Alvarez","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.prp.2025.156113_bib22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41419-020-2309-3","article-title":"Low expression of pro-apoptotic proteins Bax, Bak and Smac indicates prolonged progression-free survival in chemotherapy-treated metastatic melanoma","volume":"11","author":"Gutt\u00e0","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.prp.2025.156113_bib23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10555-018-9728-y","article-title":"Developing TRAIL\/TRAIL-death receptor-based cancer therapies","volume":"37","author":"Yuan","year":"2018","journal-title":"Cancer Metastas.. Rev."},{"key":"10.1016\/j.prp.2025.156113_bib24","series-title":"Biochemistry, Extrinsic Pathway of Apoptosis","author":"Yanumula","year":"2023"},{"key":"10.1016\/j.prp.2025.156113_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-023-01247-5","article-title":"Regulation of anoikis by extrinsic death receptor pathways","volume":"21","author":"Han","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.prp.2025.156113_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10238-024-01328-w","article-title":"IFN-\u03b1\/\u03b2\/IFN-\u03b3\/IL-15 pathways identify GBP1-expressing tumors with an immune-responsive phenotype","volume":"24","author":"Wang","year":"2024","journal-title":"Clin. Exp. Med"},{"key":"10.1016\/j.prp.2025.156113_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.615603","article-title":"Interferon Receptor Trafficking and Signaling: Journey to the Cross Roads","volume":"11","author":"Zanin","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.prp.2025.156113_bib28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ccell.2017.01.004","article-title":"Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment","volume":"31","author":"Katlinski","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.prp.2025.156113_bib29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/imr.12001","article-title":"Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation","volume":"250","author":"Piehler","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.prp.2025.156113_bib30","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni.3558","article-title":"Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing","volume":"17","author":"Chen","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.prp.2025.156113_bib31","article-title":"The interactions between cGAS-STING pathway and pathogens","volume":"5","author":"Cheng","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.prp.2025.156113_bib32","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.neuron.2017.11.032","article-title":"Activation of the STING-Dependent Type I Interferon Response Reduces Microglial Reactivity and Neuroinflammation","volume":"96","author":"Mathur","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.prp.2025.156113_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","article-title":"The cytosolic DNA-sensing cGAS\u2013sting pathway in cancer","volume":"10","author":"Won","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2025.156113_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.781032","article-title":"The Function of cGAS-STING Pathway in Treatment of Pancreatic Cancer","volume":"12","author":"Mohseni","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.prp.2025.156113_bib35","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3390\/cancers15082323","article-title":"The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy","volume":"15","author":"Yu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2025.156113_bib36","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1038\/s41467-021-26112-2","article-title":"Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance","volume":"12","author":"Cao","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2025.156113_bib37","first-page":"1","article-title":"Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment, NPJ Precis","volume":"5","author":"Yang","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.prp.2025.156113_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6051092","article-title":"BCHE as a Prognostic Biomarker in Endometrial Cancer and Its Correlation with Immunity","volume":"2022","author":"Liu","year":"2022","journal-title":"J. Immunol. Res"},{"key":"10.1016\/j.prp.2025.156113_bib39","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming Growth Factor-\u03b2 Signaling in Immunity and Cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"16","key":"10.1016\/j.prp.2025.156113_bib40","article-title":"Cancer-specific associations of driver genes with immunotherapy outcome","volume":"2020.06","author":"Jun","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.prp.2025.156113_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg3570","article-title":"NF-\u03baB-dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity","volume":"6","author":"Ghislat","year":"2021","journal-title":"Sci. Immunol."},{"issue":"2","key":"10.1016\/j.prp.2025.156113_bib42","first-page":"1","article-title":"NF-\u03baB signaling in inflammation","volume":"2:1","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther. 2017"},{"key":"10.1016\/j.prp.2025.156113_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/or.2022.10568","article-title":"NF-\u03baB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer","volume":"16","author":"Devanaboyina","year":"2022","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.prp.2025.156113_bib44","unstructured":"Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapy - PubMed, (n.d.). \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/12796364\/\u3009 (accessed May 5, 2025)."},{"key":"10.1016\/j.prp.2025.156113_bib45","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/vaccines8040617","article-title":"IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives","volume":"8","author":"Lapenta","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.prp.2025.156113_bib46","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-3-540-71029-5_14","article-title":"IFN-alpha in the Generation of Dendritic Cells for Cancer Immunotherapy","author":"Santini","year":"2009","journal-title":"Handb. Exp. Pharm. 188"},{"key":"10.1016\/j.prp.2025.156113_bib47","author":"Iwamoto","year":"2023","journal-title":"PTPN3 Inhib. Contrib. Act. dendritic Cell Funct. Augment Eff. Cancer Immunother."},{"issue":"1","key":"10.1016\/j.prp.2025.156113_bib48","first-page":"1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther. 2021"},{"key":"10.1016\/j.prp.2025.156113_bib49","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: Much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.prp.2025.156113_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.814014","article-title":"Identification of Key Pathways and Genes Related to Immunotherapy Resistance of LUAD Based on WGCNA Analysis","volume":"11","author":"Yu","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.prp.2025.156113_bib51","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8394816","article-title":"PADI1 and Its Co-Expressed Gene Signature Unveil Colorectal Cancer Prognosis and Immunotherapy Efficacy","volume":"2022","author":"Zhang","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.prp.2025.156113_bib52","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1158\/2159-8290.CD-20-1571","article-title":"Loss of optineurin drives cancer immune evasion via palmitoylation-dependent ifngr1 lysosomal sorting and degradation","volume":"11","author":"Du","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2025.156113_bib53","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3390\/cells13070581","article-title":"NF-\u03baB and JAK\/STAT Signaling Pathways as Crucial Regulators of Neuroinflammation and Astrocyte Modulation in Spinal Cord Injury","volume":"13","author":"Ageeva","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.prp.2025.156113_bib54","first-page":"1","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Target. Ther. 2023"},{"key":"10.1016\/j.prp.2025.156113_bib55","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.7150\/thno.100793","article-title":"PBRM1 deficiency enhances PD1 immunotherapeutic sensitivity via chromosomal accessibility in colorectal cancer","volume":"15","author":"Li","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.prp.2025.156113_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007466","article-title":"Machine learning-based integration develops a metabolism-derived consensus model for improving immunotherapy in pancreatic cancer","volume":"11","author":"Guo","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2025.156113_bib57","first-page":"54","article-title":"IFN\u03b12b augments immune responses of cisplatin+5-fluorouracil treated tongue squamous cell carcinoma patients - A preliminary study","volume":"136","author":"Mukherjee","year":"2012","journal-title":"Indian J. Med Res"},{"issue":"14","key":"10.1016\/j.prp.2025.156113_bib58","first-page":"1200","article-title":"Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy","volume":"14","author":"Mehta","year":"2025","journal-title":"J. Clin. Med. 2025"},{"key":"10.1016\/j.prp.2025.156113_bib59","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1200\/JCO.22.02264","article-title":"Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684","volume":"41","author":"Kirkwood","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156113_bib60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00023210-200519020-00002","article-title":"Neuropsychiatric Adverse Effects of Interferon-\u03b1: Recognition and Management","volume":"19","author":"Raison","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.prp.2025.156113_bib61","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000522195","article-title":"Adjunctive Treatment with Interferon Alpha 2b in Conjunctival Melanoma","volume":"8","author":"Huerva","year":"2022","journal-title":"Ocul. Oncol. Pathol."},{"key":"10.1016\/j.prp.2025.156113_bib62","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00262-019-02308-w","article-title":"A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma","volume":"68","author":"Suarez-Kelly","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.prp.2025.156113_bib63","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/bjd.20608","article-title":"The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications","volume":"185","author":"Hargadon","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.prp.2025.156113_bib64","article-title":"IFN-\u03b1 and 5-Aza-2\u2019-deoxycytidine enhance the anti-tumor efficacy of a dendritic- cell targeting MIP3a-Gp100-Trp2 DNA vaccine by affecting T-cell recruitment and tumor microenvironment gene expression","author":"Gordy","year":"2019","journal-title":"BioRxiv"},{"key":"10.1016\/j.prp.2025.156113_bib65","first-page":"301","volume":"13","author":"Koelblinger","year":"2020","journal-title":"Adjuv. neoadjuvant Treat. Melanoma Memo. Mag. Eur. Med. Oncol."},{"key":"10.1016\/j.prp.2025.156113_bib66","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.3390\/curroncol28060455","article-title":"Phase Ib study of atezolizumab plus interferon-\u03b1 with or without bevacizumab in patients with metastatic renal cell carcinoma and other solid tumors","volume":"28","author":"Blank","year":"2021","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.prp.2025.156113_bib67","article-title":"Immunotherapy of Metastatic Melanoma, Melanoma - Standard of Care, Challenges, and","author":"Jinga","year":"2022","journal-title":"Updates Clin. Res."},{"key":"10.1016\/j.prp.2025.156113_bib68","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CMR.0000000000000935","article-title":"Tumour regression predicts better response to interferon therapy in melanoma patients: A retrospective single centre study","volume":"34","author":"Mezlaki","year":"2024","journal-title":"Melanoma Res"},{"key":"10.1016\/j.prp.2025.156113_bib69","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3390\/ijms25052751","article-title":"Simultaneous Purification of Human Interferon Alpha-2b and Serum Albumin Using Bioprivileged Fluorinated Ionic Liquid-Based Aqueous Biphasic Systems","volume":"25","author":"Carvalho","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156113_bib70","doi-asserted-by":"crossref","DOI":"10.1177\/17562872241280005","article-title":"Clinical use of nadofaragene firadenovec-vncg","volume":"16","author":"Konety","year":"2024","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.prp.2025.156113_bib71","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/02841860902795257","article-title":"Metastatic renal cell carcinoma treated with Peg-interferon alfa-2b","volume":"48","author":"Lyrdal","year":"2009","journal-title":"Acta Oncol. (Madr. )"},{"key":"10.1016\/j.prp.2025.156113_bib72","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00262-004-0630-9","article-title":"A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor","volume":"54","author":"Bex","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.prp.2025.156113_bib73","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00280-007-0594-5","article-title":"Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma","volume":"62","author":"George","year":"2008","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.prp.2025.156113_bib74","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.2002.02.051","article-title":"Pegylated interferon alfa-2b treatment for patients with solid tumors: A phase I\/II study","volume":"20","author":"Bukowski","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156113_bib75","article-title":"Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.prp.2025.156113_bib76","doi-asserted-by":"crossref","first-page":"1293729","DOI":"10.3389\/fimmu.2023.1293729","article-title":"Leveraging diverse cell-death related signature predicts the prognosis and immunotherapy response in renal clear cell carcinoma","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.prp.2025.156113_bib77","author":"Nikoli\u0107","year":"2023","journal-title":"Util. Mitochondria Detect. Methods Appl. Addit. Tool. Differ. Ren. Cell Tumours"},{"key":"10.1016\/j.prp.2025.156113_bib78","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/medicines8010005","article-title":"Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report","volume":"8","author":"Massucci","year":"2021","journal-title":"Medicines"},{"key":"10.1016\/j.prp.2025.156113_bib79","doi-asserted-by":"crossref","first-page":"25","DOI":"10.32896\/cvns.v4n2.25-30","article-title":"Renal Cell Carcinoma With Facial Swelling and Nasal Obstruction as Primary Presentation","volume":"4","author":"Sabri","year":"2022","journal-title":"J. Cardiovasc. Neurovascular Amp Stroke"},{"key":"10.1016\/j.prp.2025.156113_bib80","doi-asserted-by":"crossref","first-page":"a006593","DOI":"10.1101\/cshperspect.a006593","article-title":"The VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path Forward","volume":"2","author":"Kieran","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.prp.2025.156113_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.prp.2025.156113_bib82","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.seminoncol.2022.01.004","article-title":"Harnessing natural killer cells for the treatment of multiple myeloma","volume":"49","author":"Clara","year":"2022","journal-title":"Semin Oncol."},{"issue":"16","key":"10.1016\/j.prp.2025.156113_bib83","first-page":"4181","article-title":"Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies","volume":"16","author":"Jureczek","year":"2024","journal-title":"Cancers 2024"},{"key":"10.1016\/j.prp.2025.156113_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01751","article-title":"Progress and challenges in the design and clinical development of antibodies for cancer therapy","volume":"8","author":"Almagro","year":"2018","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.prp.2025.156113_bib85","first-page":"44","article-title":"Phage Display Libraries for Antibody Therapeutic Discovery and Development","volume":"8","author":"Almagro","year":"2019","journal-title":"Antibodies 2019"},{"key":"10.1016\/j.prp.2025.156113_bib86","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0037-1963(01)90114-3","article-title":"Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition","volume":"38","author":"Talpaz","year":"2001","journal-title":"Semin Hematol."},{"key":"10.1016\/j.prp.2025.156113_bib87","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?","volume":"41","author":"Hasselbalch","year":"2018","journal-title":"Semin Immunopathol."},{"key":"10.1016\/j.prp.2025.156113_bib88","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8","article-title":"Long term treatment of myeloproliferative disease with interferon-\u03b1- 2b: Feasibility and efficacy","volume":"83","author":"Gilbert","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2025.156113_bib89","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, Inflammation, and Cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.prp.2025.156113_bib90","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156113_bib91","doi-asserted-by":"crossref","first-page":"001","DOI":"10.29328\/journal.jhcr.1001001","article-title":"Primary Cutaneous Lymphomas and Interferon Treatment","volume":"1","author":"MC","year":"2017","journal-title":"J. Hematol. Clin. Res."},{"key":"10.1016\/j.prp.2025.156113_bib92","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1182\/blood-2011-03-343145","article-title":"Preclinical studies on targeted delivery of multiple IFN\u03b12b to HLA-DR in diverse hematologic cancers","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156113_bib93","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1182\/blood-2009-06-228288","article-title":"Therapy of B-cell malignancies by anti\u2013HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways","volume":"115","author":"Stein","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156113_bib94","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1158\/0008-5472.CAN-10-2126","article-title":"A bispecific antibody-IFN\u03b12b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells","volume":"70","author":"Rossi","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.prp.2025.156113_bib95","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"S\u00f8rensen","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.prp.2025.156113_bib96","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2025.156113_bib97","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2018-99-118715","article-title":"Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU\/BAT","volume":"132","author":"Gisslinger","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156113_bib98","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2025.156113_bib99","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.leukres.2014.06.019","article-title":"Interferon \u03b1-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation","volume":"38","author":"Huang","year":"2014","journal-title":"Leuk. Res"},{"key":"10.1016\/j.prp.2025.156113_bib100","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1080\/10428194.2021.1948027","article-title":"Interferon-\u03b1 as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia","volume":"62","author":"Jiang","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.prp.2025.156113_bib101","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/1097-0142(19870201)59:3+<605::AID-CNCR2820591305>3.0.CO;2-4","article-title":"Interferon in the treatment of hairy cell leukemia","volume":"59","author":"Thompson","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2025.156113_bib102","doi-asserted-by":"crossref","first-page":"12","DOI":"10.14740\/jh1245","article-title":"Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment","volume":"13","author":"Suo","year":"2024","journal-title":"J. Hematol."},{"key":"10.1016\/j.prp.2025.156113_bib103","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/leu.2012.313","article-title":"Re-emergence of interferon-\u03b1 in the treatment of chronic myeloid leukemia","volume":"27","author":"Talpaz","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2025.156113_bib104","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1660121","article-title":"Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas","volume":"8","author":"Verver","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.prp.2025.156113_bib105","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(05)67482-X","article-title":"Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb\/III melanoma (EORTC 18952): Randomised controlled trial","volume":"366","author":"Eggermont","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.prp.2025.156113_bib106","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(05)67482-X","article-title":"Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb\/III melanoma (EORTC 18952): Randomised controlled trial","volume":"366","author":"Eggermont","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.prp.2025.156113_bib107","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1345\/aph.1Q791","article-title":"Dr., Sylatron: Une formulation p\u00e9gyl\u00e9e d\u2019interf\u00e9ron pour le traitement du m\u00e9lanome","volume":"46","author":"Patel","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.prp.2025.156113_bib108","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS3109","article-title":"Antibody-interferon-alpha fusion protein (IGN002) for the treatment of b-cell non-Hodgkin lymphomas: A phase 1, first-in-human, dose-escalation trial","volume":"34","author":"Young","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156113_bib109","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3390\/pharmaceutics13091390","article-title":"Novel ex vivo zymography approach for assessment of protease activity in tissues with activatable antibodies","volume":"13","author":"Howng","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2025.156113_bib110","article-title":"706 Conditional cytokine therapeutics for tumor-selective biological activity: preclinical characterization of a dual-masked IFN-a2b","volume":"9","author":"Berezhnoy","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2025.156113_bib111","article-title":"W.W. Werewolf, 723 WTX-613, a conditionally activated IFN\u03b1 INDUKINETM molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models","volume":"9","author":"Tyagi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2025.156113_bib112","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-152758","article-title":"Conditionally Activated IL-12 or IFN\u03b1 IndukineTM Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-Human Primates","volume":"138","author":"Steiner","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156113_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1218082","article-title":"Engineering cytokines for cancer immunotherapy: a systematic review","volume":"14","author":"Fu","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.prp.2025.156113_bib114","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1038\/sj.onc.1209608","article-title":"Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy","volume":"25","author":"Fulda","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2025.156113_bib115","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1084\/jem.191.7.1209","article-title":"Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival","volume":"191","author":"Hohlbaum","year":"2000","journal-title":"J. Exp. Med."},{"issue":"1979","key":"10.1016\/j.prp.2025.156113_bib116","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1126\/science.7533326","article-title":"The Fas Death Factor","volume":"267","author":"Nagata","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.prp.2025.156113_bib117","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/sj.onc.1205179","article-title":"Mechanisms of interferon-alpha induced apoptosis in malignant cells","volume":"21","author":"Thyrell","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2025.156113_bib118","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1073\/pnas.0710907105","article-title":"Role of the Akt pathway in mRNA translation of interferon-stimulated genes","volume":"105","author":"Kaur","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.prp.2025.156113_bib119","doi-asserted-by":"crossref","unstructured":"Enhanced anti melanoma efficacy of interferon \u03b1 2b via overexpression of ING4 by enhanced Fas\/FasL mediated apoptosis, (n.d.). \u3008https:\/\/doi.org\/10.3892\/ol.2018.8534#b25-ol-0-0-8534\u3009 (accessed May 9, 2025).","DOI":"10.3892\/ol.2018.8534"},{"key":"10.1016\/j.prp.2025.156113_bib120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.510310111","article-title":"Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma","volume":"31","author":"Llovet","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.prp.2025.156113_bib121","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.eururo.2005.09.011","article-title":"Interferon alpha 2b as Medical Selection for Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma: A Consecutive Study","volume":"49","author":"Bex","year":"2006","journal-title":"Eur. Urol."},{"key":"10.1016\/j.prp.2025.156113_bib122","first-page":"326","article-title":"Effect of trastuzumab in combination with IFN alpha-2b on HER2 and- MRP1 of ACHN","volume":"25","author":"Wang","year":"2005","journal-title":"J. Huazhong Univ. Sci. Technol. Med Sci."},{"key":"10.1016\/j.prp.2025.156113_bib123","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3390\/biomedicines11041071","article-title":"Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice","volume":"11","author":"Lasorsa","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.prp.2025.156113_bib124","first-page":"1063","article-title":"The treatment of renal cell carcinoma with human leukocyte alpha-interferon","volume":"130","author":"DeKernion","year":"1983","journal-title":"Elsevier"},{"key":"10.1016\/j.prp.2025.156113_bib125","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156113_bib126","first-page":"24","article-title":"Interferon (Alpha, Beta and Omega) Receptor 2 Is a Prognostic Biomarker for Lung Cancer","volume":"79","author":"Tanaka","year":"2012","journal-title":"Paleobiology"},{"key":"10.1016\/j.prp.2025.156113_bib127","unstructured":"IFNAR2 interferon alpha and beta receptor subunit 2 [Homo sapiens (human)] - Gene - NCBI, (n.d.). \u3008https:\/\/www.ncbi.nlm.nih.gov\/gene\/3455\u3009 (accessed June 26, 2025)."},{"key":"10.1016\/j.prp.2025.156113_bib128","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abe4627","article-title":"IFNAR1 and IFNAR2 play distinct roles in initiating type I interferon-induced JAK-STAT signaling and activating STATs","volume":"14","author":"Shemesh","year":"2021","journal-title":"Sci. Signal"},{"key":"10.1016\/j.prp.2025.156113_bib129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/genes16030303","article-title":"Integrating Artificial Intelligence and Bioinformatics Methods to Identify Disruptive STAT1 Variants Impacting Protein Stability and Function","volume":"16","author":"Kamal","year":"2025","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.prp.2025.156113_bib130","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s10875-023-01445-3","article-title":"Type I Interferonopathy due to a Homozygous Loss-of-Inhibitory Function Mutation in STAT2","volume":"43","author":"Zhu","year":"2023","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.prp.2025.156113_bib131","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2402226121","article-title":"Threonine phosphorylation of STAT1 restricts interferon signaling and promotes innate inflammatory responses","volume":"121","author":"Metwally","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.prp.2025.156113_bib132","first-page":"32","article-title":"In Silico Prioritization of STAT1 3\u2032 UTR SNPs Identifies rs190542524 as a miRNA-Linked Variant with Potential Oncogenic Impact","volume":"11","author":"Kamal","year":"2025","journal-title":"NonCoding RNA 2025"},{"key":"10.1016\/j.prp.2025.156113_bib133","article-title":"Population-Based Comparison of Different Risk Stratification Systems Among Prostate Cancer Patients","volume":"11","author":"Xie","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.prp.2025.156113_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.980250","article-title":"Effect of pegylated interferon-\u03b12b add-on therapy on renal function in chronic hepatitis B patients: A real-world experience","volume":"13","author":"Peng","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.prp.2025.156113_bib135","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e15036","article-title":"Predictive value of circulating B cells and T cell subsets in melanoma patients treated with neoadjuvant ipilimumab and interferon","volume":"38","author":"Khunger","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156113_bib136","doi-asserted-by":"crossref","DOI":"10.1007\/s10792-025-03465-x","article-title":"Interferon alpha-2b versus 5-fluorouracil as primary treatment modalities for ocular surface squamous neoplasia: a study of 116 eyes","volume":"45","author":"Bakal","year":"2025","journal-title":"Int Ophthalmol."},{"key":"10.1016\/j.prp.2025.156113_bib137","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-152758","article-title":"Conditionally Activated IL-12 or IFN\u03b1 IndukineTM Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-Human Primates","volume":"138","author":"Steiner","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156113_bib138","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0297366","article-title":"Intralesional interferon alpha-2b as a novel treatment for periocular squamous cell carcinoma in horses","volume":"19","author":"Martabano","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.prp.2025.156113_bib139","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008339","article-title":"Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types","volume":"12","author":"Shen","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2025.156113_bib140","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.21037\/tcr-23-2104","article-title":"Type I interferon signaling promotes radioresistance in head and neck cancer","volume":"13","author":"Zenga","year":"2024","journal-title":"Transl. Cancer Res"},{"key":"10.1016\/j.prp.2025.156113_bib141","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143666","article-title":"Interferon-Alpha Decreases Cancer Stem Cell Properties and Modulates Exosomes in Malignant Melanoma","volume":"15","author":"Garc\u00eda-Ortega","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2025.156113_bib142","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3390\/ijms23052704","article-title":"Identification of a Tumor Cell Associated Type I IFN Resistance Gene Expression Signature of Human Melanoma, the Components of Which Have a Predictive Potential for Immunotherapy","volume":"23","author":"Lad\u00e1nyi","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156113_bib143","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40360-025-00937-9","article-title":"The safety, tolerability, pharmacokinetics, and pharmacodynamics of nebulized pegylated interferon \u03b1-2b in healthy adults: a randomized phase 1 trial","volume":"26","author":"Huang","year":"2025","journal-title":"BMC Pharm. Toxicol."},{"key":"10.1016\/j.prp.2025.156113_bib144","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00280-010-1326-9","article-title":"Pharmacokinetic\/pharmacodynamic analysis of adjuvant pegylated interferon \u03b1-2b in patients with resected high-risk melanoma","volume":"67","author":"Daud","year":"2010","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.prp.2025.156113_bib145","article-title":"Implementation of a pharmacist-guided pharmacogenomics dosing service at a rural NCI-designated comprehensive cancer center","author":"Green","year":"2024","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.prp.2025.156113_bib146","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/1078-0432.CCR-24-1983","article-title":"A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors","volume":"31","author":"Bechter","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2025.156113_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1249330","article-title":"Combining PD-1\/PD-L1 blockade with type I interferon in cancer therapy","volume":"14","author":"Razaghi","year":"2023","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.prp.2025.156113_bib148","first-page":"1","article-title":"Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade","volume":"15","author":"Holzgruber","year":"2024","journal-title":"Nat. Commun. 2024"},{"issue":"1","key":"10.1016\/j.prp.2025.156113_bib149","first-page":"1","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer 2022"},{"key":"10.1016\/j.prp.2025.156113_bib150","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance Mechanisms of Anti-PD1\/PDL1 Therapy in Solid Tumors","volume":"8","author":"Lei","year":"2020","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.prp.2025.156113_bib151","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2025.156113_bib152","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1200\/JCO.18.00632","article-title":"Phase Ib\/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma","volume":"36","author":"Davar","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156113_bib153","first-page":"1","article-title":"PD-1\/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies","volume":"23","author":"Jin","year":"2024","journal-title":"Mol. Cancer 2024"},{"key":"10.1016\/j.prp.2025.156113_bib154","unstructured":"Rintatolimod Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (NCT05756166) | CareAcross Lung Cancer service, (n.d.). \u3008https:\/\/www.careacross.com\/clinical-trials\/trial\/NCT05756166\u3009 (accessed May 10, 2025)."},{"key":"10.1016\/j.prp.2025.156113_bib155","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-023-01979-5","article-title":"Looking ahead in early-phase trial design to improve the drug development process: examples in oncology","volume":"23","author":"Vanderbeek","year":"2023","journal-title":"BMC Med Res Method."},{"key":"10.1016\/j.prp.2025.156113_bib156","article-title":"Nanoparticle delivery of innate immune agonists combines with senescence-inducing agents to mediate T cell control of pancreatic cancer","author":"Chibaya","year":"2023","journal-title":"BioRxiv"},{"key":"10.1016\/j.prp.2025.156113_bib157","article-title":"PEGylated therapeutics in the clinic","volume":"9","author":"Gao","year":"2023","journal-title":"Bioeng. Transl. Med"},{"key":"10.1016\/j.prp.2025.156113_bib158","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1517\/14728210902907847","article-title":"Emerging PEGylated drugs","volume":"14","author":"Jung","year":"2009","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.prp.2025.156113_bib159","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41423-022-00848-3","article-title":"The combination of PD-1 blockade with interferon-\u03b1 has a synergistic effect on hepatocellular carcinoma","volume":"19","author":"Zhu","year":"2022","journal-title":"Cell Mol. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2025.156113_bib160","article-title":"Interferon enhances immune-checkpoint inhibition","volume":"16","author":"Romero","year":"2018","journal-title":"Nat. Rev. Clin. Oncol. 2018"},{"key":"10.1016\/j.prp.2025.156113_bib161","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007959","article-title":"Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1\/PD-L1 inhibitors","volume":"12","author":"Li","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2025.156113_bib162","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.675873","article-title":"Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma","volume":"11","author":"Jia","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.prp.2025.156113_bib163","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11237176","article-title":"Lung Cancer Clinical Trials with a Seamless Phase II\/III Design: Systematic Review","volume":"11","author":"Palermos","year":"2022","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.prp.2025.156113_bib164","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-062602","article-title":"Low-doseinterleukin 2 for the reduction ofvascular inflammation in acute coronarysyndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial","volume":"12","author":"Sriranjan","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.prp.2025.156113_bib165","author":"Raeber","year":"2022","journal-title":"A Syst. Rev. Inter. 2Based Immunother. Clin. Trials Cancer autoimmune Dis."},{"key":"10.1016\/j.prp.2025.156113_bib166","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007959","article-title":"Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1\/PD-L1 inhibitors","volume":"12","author":"Li","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2025.156113_bib167","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1200\/JCO.2011.38.2960","article-title":"Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma","volume":"30","author":"Schmidt","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156113_bib168","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2025.156113_bib169","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.prp.2025.156113_bib170","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial","volume":"304","author":"Neoptolemos","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.prp.2025.156113_bib171","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1158\/0008-5472.CAN-19-0381","article-title":"Nanoparticle encapsulation of synergistic immune agonists enables systemic codelivery to tumor sites and IFN\u03b2-driven antitumor immunity","volume":"79","author":"Atukorale","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.prp.2025.156113_bib172","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.prp.2025.156113_bib173","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/abbs\/gmr082","article-title":"Targeted novel surface-modified nanoparticles for interferon delivery for the treatment of hepatitis B","volume":"43","author":"Giri","year":"2011","journal-title":"Acta Biochim Biophys. Sin. (Shanghai)"},{"key":"10.1016\/j.prp.2025.156113_bib174","article-title":"Exosomes and tumor virus interlink: A complex side of cancer","volume":"266","author":"Topiwala","year":"2025","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.prp.2025.156113_bib175","article-title":"Therapeutic potential of 18-\u03b2-glycyrrhetinic acid-loaded poly (lactic-co-glycolic acid) nanoparticles on cigarette smoke-induced in-vitro model of COPD","volume":"263","author":"El Sherkawi","year":"2024","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.prp.2025.156113_bib176","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.prp.2017.06.001","article-title":"Combined primary hepatic neuroendocrine carcinoma and hepatocellular carcinoma with aggressive biological behavior (adverse clinical course): A case report","volume":"213","author":"Okumura","year":"2017","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.prp.2025.156113_bib177","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1021\/acs.molpharmaceut.8b00277","article-title":"Exosomes as a Drug Delivery System in Cancer Therapy: Potential and Challenges","volume":"15","author":"Kibria","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.prp.2025.156113_bib178","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2016.00533","article-title":"Exosome-based cancer therapy: Implication for targeting cancer stem cells","volume":"7","author":"Wang","year":"2017","journal-title":"Front Pharm."},{"key":"10.1016\/j.prp.2025.156113_bib179","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12943-024-02215-4","article-title":"Emerging role of exosomes in cancer therapy: progress and challenges","volume":"24","author":"Li","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2025.156113_bib180","first-page":"281","article-title":"Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics","volume":"10","author":"Thakur","year":"2022","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.prp.2025.156113_bib181","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/pharmaceutics16111349","article-title":"Multilayer Nanocarrier for the Codelivery of Interferons: A Promising Strategy for Biocompatible and Long-Acting Antiviral Treatment","volume":"16","author":"Ramos","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2025.156113_bib182","first-page":"4841","article-title":"Preparation of bioactive interferon alpha\u2013loaded polysaccharide nanoparticles using a new approach of temperature-induced water phase\/water-phase emulsion","author":"Liu","year":"2012","journal-title":"Int J. Nanomed. 7"},{"key":"10.1016\/j.prp.2025.156113_bib183","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijpharm.2011.03.016","article-title":"Development of interferon alpha-2b microspheres with constant release","volume":"410","author":"Li","year":"2011","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.prp.2025.156113_bib184","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1158\/0008-5472.CAN-19-0381","article-title":"Nanoparticle encapsulation of synergistic immune agonists enables systemic codelivery to tumor sites and IFN\u03b2-driven antitumor immunity","volume":"79","author":"Atukorale","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.prp.2025.156113_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115306","article-title":"PEGylated leuprolide with improved pharmacokinetic properties","volume":"28","author":"Fu","year":"2020","journal-title":"Bioorg. Med Chem."},{"key":"10.1016\/j.prp.2025.156113_bib186","first-page":"193","article-title":"A Frail Hairy Cell Leukemia Patient Successfully Treated with Pegylated Interferon-\u03b1-2A","volume":"12","author":"De Novellis","year":"2022","journal-title":"J. Clin. Med. 2023"},{"key":"10.1016\/j.prp.2025.156113_bib187","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1067\/mcp.2000.110973","article-title":"S. Jacobs, Pegylated interferon-\u03b12b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data","volume":"68","author":"Glue","year":"2000","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.prp.2025.156113_bib188","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/WNL.0b013e318207b031","article-title":"Phase I trial of pegylated interferon-\u03b1-2b in young patients with plexiform neurofibromas","volume":"76","author":"Jakacki","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.prp.2025.156113_bib189","first-page":"39","article-title":"Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review","author":"Okuyama","year":"2010","journal-title":"Core Evid. 5"},{"key":"10.1016\/j.prp.2025.156113_bib190","article-title":"Safety and efficacy of 48-week pegylated interferon-\u03b1-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study","volume":"11","author":"Wang","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.prp.2025.156113_bib191","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1358\/dot.2020.56.3.3107706","article-title":"Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera","volume":"56","author":"Wagner","year":"2020","journal-title":"Drugs Today"},{"key":"10.1016\/j.prp.2025.156113_bib192","unstructured":"Ropeginterferon alfa-2b-njft (subcutaneous route) - Mayo Clinic, (n.d.). \u3008https:\/\/www.mayoclinic.org\/drugs-supplements\/ropeginterferon-alfa-2b-njft-subcutaneous-route\/description\/drg-20526931\u3009 (accessed May 10, 2025)."},{"key":"10.1016\/j.prp.2025.156113_bib193","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-2071","article-title":"Abstract 2071: Probody-interferon-alpha 2b combines antitumor activity with improved tolerability","volume":"82","author":"Berezhnoy","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.prp.2025.156113_bib194","article-title":"1078 Conditionally activatable interferon-alpha 2b improves tolerability and exhibits preferential activity in tumors","volume":"10","author":"Berezhnoy","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2025.156113_bib195","doi-asserted-by":"crossref","unstructured":"A. Berezhnoy, H. Wang, N. Cai, H. Assi, N. Lapuyade, M. Paidhungat, K. Wong, M. Krimm, R. Dunn, D. Daniel, M. Belvin, E.Le Scolan, 706 Conditional cytokine therapeutics for tumor-selective biological activity: preclinical characterization of a dual-masked IFN-a2b, (2021) A735\u2013A735. https:\/\/doi.org\/10.1136\/JITC-2021-SITC2021.706.","DOI":"10.1136\/jitc-2021-SITC2021.706"},{"key":"10.1016\/j.prp.2025.156113_bib196","unstructured":"CytomX Therapeutics Announces First Patient Dosed with, (n.d.). \u3008https:\/\/www.globenewswire.com\/news-release\/2024\/09\/09\/2942754\/37704\/en\/CytomX-Therapeutics-Announces-First-Patient-Dosed-with-CX-801-a-Dually-Masked-Interferon-Alpha-2b-PROBODY-in-a-Phase-1-Study-in-Patients-with-Solid-Tumors.html\u3009 (accessed May 10, 2025)."},{"key":"10.1016\/j.prp.2025.156113_bib197","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0022-5347(17)40248-5","article-title":"The development of liposomes containing interferon alpha for the intravesical therapy of human superficial bladder cancer","volume":"143","author":"Frangos","year":"1990","journal-title":"J. Urol."},{"key":"10.1016\/j.prp.2025.156113_bib198","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/jpet.102.037002","article-title":"Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-\u03b1 fusion protein in cynomolgus monkeys","volume":"303","author":"Osborn","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.prp.2025.156113_bib199","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/135965350601100111","article-title":"A Phase I\/II study evaluating escalating doses of recombinant human albumin-interferon-\u03b1 fusion protein in chronic hepatitis C patients who have failed previous interferon-\u03b1-based therapy","volume":"11","author":"Balan","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.prp.2025.156113_bib200","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1177\/135965350601100710","article-title":"Modulation of interferon-specific gene expression by albumin-interferon- \u03b1 in interferon-\u03b1-experienced patients with chronic hepatitis C","volume":"11","author":"Balan","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.prp.2025.156113_bib201","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/vaccines9010010","article-title":"Interferon-\u03b1-Induced Dendritic Cells Generated with Human Platelet Lysate Exhibit Elevated Antigen Presenting Ability to Cytotoxic T Lymphocytes","volume":"9","author":"Date","year":"2020","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.prp.2025.156113_bib202","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1128\/jvi.74.10.4729-4737.2000","article-title":"Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8 + Cytotoxic T Lymphocytes","volume":"74","author":"Santin","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.prp.2025.156113_bib203","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.4049\/jimmunol.180.3.1462","article-title":"IFN-\u03b1 Skews Monocytes into CD56+-Expressing Dendritic Cells with Potent Functional Activities In Vitro and In Vivo","volume":"180","author":"Papewalis","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.prp.2025.156113_bib204","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1080\/21645515.2018.1547603","article-title":"Phenotypic and functional profile of IFN-\u03b1-differentiated dendritic cells (IFN-DCs) from HIV-infected individuals","volume":"15","author":"Santillo","year":"2018","journal-title":"Hum. Vaccin Immunother."},{"key":"10.1016\/j.prp.2025.156113_bib205","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7150\/ijms.31830","article-title":"IFN-DC Loaded with Autophagosomes containing Virus Antigen is Highly Efficient in Inducing Virus-Specific Human T Cells","volume":"16","author":"Fan","year":"2019","journal-title":"Int J. Med Sci."},{"key":"10.1016\/j.prp.2025.156113_bib206","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4049\/jimmunol.164.1.23","article-title":"IFN-\u03b2 Differentially Regulates CD40-Induced Cytokine Secretion by Human Dendritic Cells","volume":"164","author":"McRae","year":"2000","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2025.156113_bib207","first-page":"1","article-title":"Interferon-\u03b1-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity","volume":"7","author":"Koya","year":"2017","journal-title":"Sci. Rep. 2017"},{"key":"10.1016\/j.prp.2025.156113_bib208","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.2008.20.2069","volume":"27","author":"Bottomley","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.prp.2025.156113_bib209","first-page":"846","article-title":"Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade","volume":"29","author":"Jacquelot","year":"2019","journal-title":"Cell Res. 2019"},{"key":"10.1016\/j.prp.2025.156113_bib210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12071954","article-title":"Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature","volume":"12","author":"How","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2025.156113_bib211","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/ICO.0000000000003360","article-title":"Adjuvant Topical Interferon Alpha 2b for the Treatment of Monkeypox Ocular Manifestations","volume":"42","author":"Arteaga-Rivera","year":"2023","journal-title":"Cornea"},{"key":"10.1016\/j.prp.2025.156113_bib212","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4103\/2452-2325.329089","article-title":"Recombinant Interferon Alpha-2B as Primary Treatment for Ocular Surface Squamous Neoplasia","volume":"33","author":"Ghaffari","year":"2021","journal-title":"J. Curr. Ophthalmol."},{"key":"10.1016\/j.prp.2025.156113_bib213","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/bjd.20608","article-title":"The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications","volume":"185","author":"Hargadon","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.prp.2025.156113_bib214","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01771","article-title":"Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model","volume":"10","author":"Sirait-Fischer","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.prp.2025.156113_bib215","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.3390\/ijms22084190","article-title":"Type I Interferon Production of Plasmacytoid Dendritic Cells under Control","volume":"22","author":"Bencze","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156113_bib216","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1474-4422(24)00526-X","article-title":"Autoinflammatory encephalopathy due to PTPN1 haploinsufficiency: a case series","volume":"24","author":"Zhu","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.prp.2025.156113_bib217","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010464","article-title":"Inducible CRISPR activation screen for interferon-stimulated genes identifies OAS1 as a SARS-CoV-2 restriction factor","volume":"18","author":"Danziger","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.prp.2025.156113_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104960","article-title":"Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease","volume":"299","author":"Samuel","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prp.2025.156113_bib219","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/pharmaceutics16111349","article-title":"Multilayer Nanocarrier for the Codelivery of Interferons: A Promising Strategy for Biocompatible and Long-Acting Antiviral Treatment","volume":"16","author":"Ramos","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2025.156113_bib220","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3390\/pharmaceutics13101533","article-title":"Forms and Methods for Interferon\u2019s Encapsulation","volume":"13","author":"Ramos","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2025.156113_bib221","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1089\/jir.1996.16.637","article-title":"The biological properties, assay, and standardization of interferon- alpha: A need for a WHO collaborative study","volume":"16","author":"Mire-Sluis","year":"1996","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.prp.2025.156113_bib222","doi-asserted-by":"crossref","DOI":"10.1093\/jalm\/jfae080","article-title":"IFN-\u03b12 Autoantibody Screening and Functional Evaluation in Viral and Bacterial Infections","volume":"9","author":"Cockx","year":"2024","journal-title":"J. Appl. Lab Med"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825003061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825003061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:53:58Z","timestamp":1778687638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825003061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":222,"alternative-id":["S0344033825003061"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.156113","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon alpha-2b (IFN\u03b12b) in precision oncology: Innovations in delivery and combinatorial immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.156113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156113"}}